55 related articles for article (PubMed ID: 16482213)
1. Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.
Turner SD; Alexander DR
Leukemia; 2006 Apr; 20(4):572-82. PubMed ID: 16482213
[TBL] [Abstract][Full Text] [Related]
2. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.
Slupianek A; Hoser G; Majsterek I; Bronisz A; Malecki M; Blasiak J; Fishel R; Skorski T
Mol Cell Biol; 2002 Jun; 22(12):4189-201. PubMed ID: 12024032
[TBL] [Abstract][Full Text] [Related]
3. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
4. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
5. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?
Hoser G; Majsterek I; Romana DL; Slupianek A; Blasiak J; Skorski T
Leuk Res; 2003 Mar; 27(3):267-73. PubMed ID: 12537980
[TBL] [Abstract][Full Text] [Related]
6. Fusion tyrosine kinases: a result and cause of genomic instability.
Penserga ET; Skorski T
Oncogene; 2007 Jan; 26(1):11-20. PubMed ID: 16785987
[TBL] [Abstract][Full Text] [Related]
7. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
8. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
9. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
10. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha.
Malinge S; Monni R; Bernard O; Penard-Lacronique V
Oncogene; 2006 Jun; 25(25):3589-97. PubMed ID: 16434962
[TBL] [Abstract][Full Text] [Related]
11. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
Turner SD; Alexander DR
Leukemia; 2005 Jul; 19(7):1128-34. PubMed ID: 15902287
[TBL] [Abstract][Full Text] [Related]
12. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling.
Yu WM; Hawley TS; Hawley RG; Qu CK
Oncogene; 2003 Sep; 22(38):5995-6004. PubMed ID: 12955078
[TBL] [Abstract][Full Text] [Related]
13. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
[TBL] [Abstract][Full Text] [Related]
14. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.
Lannon CL; Sorensen PH
Semin Cancer Biol; 2005 Jun; 15(3):215-23. PubMed ID: 15826836
[TBL] [Abstract][Full Text] [Related]
15. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling.
Irie-Sasaki J; Sasaki T; Matsumoto W; Opavsky A; Cheng M; Welstead G; Griffiths E; Krawczyk C; Richardson CD; Aitken K; Iscove N; Koretzky G; Johnson P; Liu P; Rothstein DM; Penninger JM
Nature; 2001 Jan; 409(6818):349-54. PubMed ID: 11201744
[TBL] [Abstract][Full Text] [Related]
16. The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.
Holroyd A; Cross NC; Macdonald DH
Leuk Res; 2011 Oct; 35(10):1279-85. PubMed ID: 21722956
[TBL] [Abstract][Full Text] [Related]
17. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
18. Janus kinases in cytokine signalling.
Ihle JN
Philos Trans R Soc Lond B Biol Sci; 1996 Feb; 351(1336):159-66. PubMed ID: 8650262
[TBL] [Abstract][Full Text] [Related]
19. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
20. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
